Differences in the immunogenicity of heterologous Ad26.COV.2/BNT162b2 vaccination compared to other heterologous and homologous COVID-19 vaccine regimens

被引：0
|
作者：
Klemis, V. [1 ]
Venhorst, A. [2 ]
Halmans, L. [2 ]
Schmidt, T. [1 ]
Greiss, F. [3 ]
Wilhelm, A. [4 ]
Widera, M. [4 ]
Sester, U. [5 ]
Gaertner, B. C. [6 ]
Meyer, T. [2 ]
Sester, M. [1 ]
机构：
[1] Saarland Univ, Dept Transplant & Infect Immunol, Homburg, Germany
[2] Saarland Univ, Inst Sports & Prevent Med, Saarbrucken, Germany
[3] Humboldt Univ, Dept Sports Med, Berlin, Germany
[4] Goethe Univ Frankfurt, Inst Med Virol, Frankfurt, Germany
[5] SHG Klinikum Volklingen, Dept Nephrol, Volklingen, Germany
[6] Saarland Univ, Inst Med Microbiol & Hyg, Homburg, Germany
来源：
EUROPEAN JOURNAL OF IMMUNOLOGY | 2022年 / 52卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
P 019
引用
收藏
页码：165 / 166
页数：2
相关论文
共 50 条
  • [41] Immunogenicity and safety of BNT162b2 COVID-19 vaccine in a chronic lymphocytic leukaemia patient
    Agrati, Chiara
    Castilletti, Concetta
    Sacchi, Alessandra
    Colavita, Francesca
    Capobianchi, Maria Rosaria
    Puro, Vincenzo
    Nicastri, Emanuele
    Ippolito, Giuseppe
    Bibas, Michele
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2021, 25 (13) : 6460 - 6462
  • [42] Immunogenicity of the COVID-19 BNT162b2 vaccine in adolescents and young adults with cystic fibrosis
    Michos, Athanasios
    Filippatos, Filippos
    Tatsi, Elizabeth-Barbara
    Dellis, Charilaos
    Efthymiou, Vasiliki
    Zarkada, Ioanna
    Troupi, Evgenia
    Syriopoulou, Vasiliki
    Loukou, Ioanna
    JOURNAL OF CYSTIC FIBROSIS, 2022, 21 (03) : E184 - E187
  • [43] Safety and immunogenicity of booster vaccination and fractional dosing with Ad26. COV2.S or BNT162b2 in Ad26.COV2.Svaccinated participants
    Riou, Catherine
    Bhiman, Jinal N.
    Ganga, Yashica
    Sawry, Shobna
    Ayres, Frances
    Baguma, Richard
    Balla, Sashkia R.
    Benede, Ntombi
    Bernstein, Mallory
    Besethi, Asiphe S.
    Cele, Sandile
    Crowther, Carol
    Dhar, Mrinmayee
    Geyer, Sohair
    Gill, Katherine
    Grifoni, Alba
    Hermanus, Tandile
    Kaldine, Haajira
    Keeton, Roanne S.
    Kgagudi, Prudence
    Khan, Khadija
    Lazarus, Erica
    Le Roux, Jean
    Lustig, Gila
    Madzivhandila, Mashudu
    Magugu, Siyabulela F. J.
    Makhado, Zanele
    Manamela, Nelia P.
    Mkhize, Qiniso
    Mosala, Paballo
    Motlou, Thopisang P.
    Mutavhatsindi, Hygon
    Mzindle, Nonkululeko B.
    Nana, Anusha
    Nesamari, Rofhiwa
    Ngomti, Amkele
    Nkayi, Anathi A.
    Nkosi, Thandeka P.
    Omondi, Millicent A.
    Panchia, Ravindre
    Patel, Faeezah
    Sette, Alessandro
    Singh, Upasna
    van Graan, Strauss
    Venter, Elizabeth M.
    Walters, Avril
    Moyo-Gwete, Thandeka
    Richardson, Simone I.
    Garrett, Nigel
    Rees, Helen
    PLOS GLOBAL PUBLIC HEALTH, 2024, 4 (04):
  • [44] Immunogenicity Following Administration of BNT162b2 and Ad26.COV2.S COVID-19 Vaccines in the Pregnant Population during the Third Trimester
    Citu, Ioana Mihaela
    Citu, Cosmin
    Gorun, Florin
    Sas, Ioan
    Tomescu, Larisa
    Neamtu, Radu
    Motoc, Andrei
    Gorun, Oana Maria
    Burlea, Bogdan
    Bratosin, Felix
    Malita, Daniel
    VIRUSES-BASEL, 2022, 14 (02):
  • [45] Symptomatology during previous SARS-CoV-2 infection and serostatus before vaccination influence the immunogenicity of BNT162b2 COVID-19 mRNA vaccine
    Nantel, Sabryna
    Bourdin, Benoite
    Adams, Kelsey
    Carbonneau, Julie
    Rabezanahary, Henintsoa
    Hamelin, Marie-Eve
    McCormack, Deirdre
    Savard, Patrice
    Longtin, Yves
    Cheng, Matthew P.
    De Serres, Gaston
    Corbeil, Jacques
    Gilca, Vladimir
    Baz, Mariana
    Boivin, Guy
    Quach, Caroline
    Decaluwe, Helene
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [46] Dermatomyositis Following BNT162b2 mRNA COVID-19 Vaccination
    Gouda, Wesam
    Albasri, Anwar
    Alsaqabi, Faisal
    Al Sabah, Humoud Y.
    Alkandari, Marwan
    Abdelnaby, Hassan
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2022, 37 (05)
  • [47] Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy
    Dagan, Noa
    Barda, Noam
    Biron-Shental, Tal
    Makov-Assif, Maya
    Key, Calanit
    Kohane, Isaac S.
    Hernan, Miguel A.
    Lipsitch, Marc
    Hernandez-Diaz, Sonia
    Reis, Ben Y.
    Balicer, Ran D.
    NATURE MEDICINE, 2021, 27 (10) : 1693 - +
  • [48] Erythema multiforme following COVID-19 vaccination (BNT162b2)
    Wunderlich, K.
    Dirschka, T.
    HAUTARZT, 2022, 73 (01): : 68 - 70
  • [49] Eosinophilic cellulitis in response to BNT162b2 COVID-19 vaccination
    Ikediobi, Ogechi
    Eichenfield, Dawn Z.
    Barrio, Victoria R.
    PEDIATRIC DERMATOLOGY, 2022, 39 (05) : 823 - 824
  • [50] Effectiveness of BNT162b2 COVID-19 Vaccination in Children and Adolescents
    Klein, Nicola P.
    Demarco, Maria
    Fleming-Dutra, Katherine E.
    Stockwell, Melissa S.
    Kharbanda, Anupam B.
    Gaglani, Manjusha
    Rao, Suchitra
    Lewis, Ned
    Irving, Stephanie A.
    Hartmann, Emily
    Natarajan, Karthik
    Dalton, Alexandra F.
    Zerbo, Ousseny
    DeSilva, Malini B.
    Konatham, Deepika
    Stenehjem, Edward
    Rowley, Elizabeth A. K.
    Ong, Toan C.
    Grannis, Shaun J.
    Sloan-Aagard, Chantel
    Han, Jungmi
    Verani, Jennifer R.
    Raiyani, Chandni
    Dascomb, Kristin
    Reese, Sarah E.
    Barron, Michelle A.
    Fadel, William F.
    Naleway, Allison L.
    Nanez, Juan
    Dickerson, Monica
    Goddard, Kristin
    Murthy, Kempapura
    Grisel, Nancy
    Weber, Zacharay A.
    Dixon, Brian E.
    Patel, Palak
    Fireman, Bruce
    Arndorfer, Julie
    Valvi, Nimish R.
    Griggs, Eric P.
    Hallowell, Carly
    Embi, Peter J.
    Ball, Sarah W.
    Thompson, Mark G.
    Tenforde, Mark W.
    Link-Gelles, Ruth
    PEDIATRICS, 2023, 151 (05)
12345